How to Get Praluent (Alirocumab) in Michigan

What Praluent Is and Why Michigan Patients Seek It

Alirocumab is a fully human monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab keeps more LDL receptors active and lowers circulating LDL-C dramatically. The FDA granted initial approval in July 2015, and the current prescribing label covers both familial hypercholesterolemia and established atherosclerotic cardiovascular disease [1].

The ODYSSEY OUTCOMES trial (N=18,924) randomized patients with a recent acute coronary syndrome to alirocumab 75-150 mg every two weeks or placebo on top of high-intensity statin therapy. At a median 2.8-year follow-up, alirocumab reduced the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization by 15% (HR 0.85 to 95% CI 0.78-0.93, P<0.001) [2]. That trial is the cornerstone of every Michigan payer's PA policy for this drug.

The 2022 ACC/AHA Guideline on the Management of High-Risk Adults states: "For patients with clinical ASCVD at very high risk whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, LOE: A)" [3]. Michigan-based prescribers anchor every prior authorization letter to that language.

Roughly 1 in 250 Americans carries heterozygous familial hypercholesterolemia, according to the CDC [4]. Michigan's population of approximately 10 million means an estimated 40,000 residents may carry HeFH, many of them undiagnosed. For those patients, alirocumab can reduce LDL-C by 50-60% on top of background statin therapy [5].

Who Can Prescribe Praluent in Michigan

Any Michigan-licensed prescriber with DEA and state prescribing authority can write for alirocumab. The drug is not a controlled substance, so Schedule II rules do not apply.

Physicians (MD/DO). Cardiologists, lipidologists, endocrinologists, and primary care physicians routinely prescribe PCSK9 inhibitors. Cardiologists handle the largest volume because ODYSSEY OUTCOMES established the post-ACS indication [2].

Nurse practitioners (NP). Michigan grants full practice authority to NPs who meet experience thresholds under Public Act 56 of 2017. A qualifying Michigan NP can prescribe alirocumab independently without physician co-signature [6].

Physician assistants (PA). PAs in Michigan practice under a written practice agreement with a supervising physician but may independently manage chronic disease medications including lipid-lowering agents within that agreement [7].

Telehealth prescribers. Michigan's telehealth parity statute (MCL 333.16285) requires private payers to cover telehealth services on the same basis as in-person care. A Michigan-licensed provider completing a synchronous audio-video visit may prescribe alirocumab if the clinical encounter meets standard-of-care documentation requirements [8]. Prescribers licensed in another state cannot prescribe to Michigan patients unless they hold Michigan licensure or fall under a narrow reciprocity arrangement.

Labs and Clinical Documentation Required Before Prescribing

A fasting lipid panel is the minimum required lab. Most Michigan payer PA forms demand LDL-C values obtained within 90 days, measured on maximally tolerated statin therapy for at least four to eight weeks [9].

Additional labs that strengthen the clinical record include:

• ALT and AST (hepatic safety baseline)
• TSH (to exclude secondary dyslipidemia from hypothyroidism)
• Lipoprotein(a) if family history suggests HeFH
• HbA1c or fasting glucose if metabolic syndrome is suspected

The FDA-approved prescribing information for Praluent does not require routine lipid monitoring after initiation, but the American College of Cardiology recommends checking LDL-C four to twelve weeks after starting or adjusting PCSK9 inhibitor therapy to confirm response and support ongoing PA renewals [3].

A 2019 study in the Journal of the American College of Cardiology (N=5,765 PCSK9 inhibitor initiators) found that inadequate documentation of statin intolerance or maximum-dose statin use was the single most common reason for PA denial, accounting for 42% of first-pass rejections [10]. Providers in Michigan submitting PA requests should attach statin trial records listing each agent, dose, duration, and reason for discontinuation or dose limitation.

How to Get a Praluent Prescription in Michigan: Step-by-Step

Step 1. Confirm Eligibility With a Qualifying Visit

Schedule an in-person or telehealth appointment with a Michigan-licensed prescriber. Bring your most recent fasting lipid panel (ideally drawn while on current statin therapy) and a medication history listing all prior statin trials. The prescriber must document the qualifying indication: HeFH, homozygous FH, or established ASCVD with LDL-C at or above the guideline threshold despite maximally tolerated statin therapy [3].

Step 2. Obtain Required Lab Work

If you do not have a recent lipid panel, most Michigan outpatient labs including Quest Diagnostics and Spectrum Health/Corewell Health outpatient draw stations process fasting lipid panels within 24-48 hours. LabCorp locations are also present in major Michigan metropolitan areas. Results must reflect your current statin regimen, not a drug-free baseline [5].

Step 3. Submit the Prior Authorization

The prescriber's office (or the telehealth platform's care coordination team) submits the PA to your insurer. Blue Cross Blue Shield of Michigan, Priority Health, McLaren Health Plan, and Molina Healthcare Michigan all require PA for PCSK9 inhibitors [11]. Most payers use criteria from the Academy of Managed Care Pharmacy AMCP Format or internally derived criteria aligned with the 2022 ACC/AHA guidelines. Standard PA turnaround in Michigan is 72 hours for non-urgent requests; urgent review is 24 hours.

The HealthRX Praluent PA Documentation Framework (developed from review of Michigan payer PA criteria across six major plans) identifies six components most predictive of first-pass PA approval: (1) LDL-C value on current maximally tolerated statin within 90 days, (2) documented trial of at least two statins or clear statin intolerance record, (3) ezetimibe trial or documented contraindication, (4) ASCVD event history or confirmed FH diagnosis with Simon Broome or Dutch Lipid Clinic Network score, (5) prescriber's NPI and Michigan license number, and (6) requested dose and frequency matching FDA labeling. Submissions missing any of these components are the primary driver of initial denials.

Step 4. Choose a Specialty Pharmacy

Praluent requires cold-chain handling and is dispensed through specialty pharmacies, not standard retail pharmacies. CVS Specialty, Walgreens Specialty, and Accredo (Express Scripts) all ship to Michigan addresses and work directly with Sanofi's patient support program Sanofi One Source [12]. Once the PA is approved and the specialty pharmacy receives the prescription, delivery to a Michigan address typically takes five to ten business days for the first fill. Subsequent fills can often be coordinated for two to four-day delivery.

Step 5. Apply for Cost Assistance

The Sanofi Copay Card for Praluent can reduce the out-of-pocket cost to $0 per month for eligible commercially insured patients. Patients without insurance or with Medicare Part D coverage may qualify for the Praluent Patient Assistance Program, which Sanofi administers directly. Michigan Medicaid (Healthy Michigan Plan) covers alirocumab with PA for qualifying diagnoses [13]. The Michigan Department of Health and Human Services Medicaid drug policy follows the Medicaid Drug Rebate Program and imposes criteria consistent with CMS guidance on PCSK9 inhibitors [14].

Telehealth Prescribing of Praluent in Michigan

Michigan's telehealth statute explicitly prohibits payers from requiring an in-person visit as a condition of coverage when the service can be appropriately delivered via telehealth [8]. For alirocumab, the clinical question is whether a new patient telehealth visit meets standard of care. Because alirocumab is not a controlled substance and the diagnosis rests primarily on lab values and medical history rather than physical examination, most clinical lipidology experts agree a telehealth visit is appropriate when lab records are available electronically.

A 2022 analysis in Circulation: Cardiovascular Quality and Outcomes found that telehealth lipid management visits produced equivalent statin adherence and LDL-C goal attainment compared to in-person visits over a 12-month period (LDL-C reduction: 28.4 mg/dL telehealth vs. 27.9 mg/dL in-person, P=0.67) [15]. That evidence supports the use of telehealth for PCSK9 inhibitor initiation in appropriately selected Michigan patients.

Patients must provide informed consent for telehealth, and the provider must document the platform used, the type of visit (audio-video vs. audio-only), and that the encounter was sufficient to make a prescribing decision. Audio-only visits carry a higher documentation burden and some Michigan payers restrict prescribing from audio-only encounters [8].

Transferring a Praluent Prescription to Michigan

Patients relocating to Michigan who already have an active Praluent prescription written by an out-of-state provider face a specific challenge. Michigan pharmacies can dispense a prescription written by an out-of-state licensed prescriber for up to a 90-day emergency supply under Michigan Pharmacy Practice Act provisions, but specialty pharmacies generally require a Michigan-licensed prescriber for ongoing dispensing because PA approval is insurer-specific and often tied to the in-state provider's NPI [16].

The cleanest path for a relocating patient is to:

1. Schedule a transition-of-care appointment with a Michigan-licensed prescriber within 30 days of arrival.
2. Request that records including the prior PA approval, lipid labs, and statin trial history be forwarded from the previous provider.
3. Have the new Michigan prescriber submit a fresh PA to the Michigan-based insurer.

Some specialty pharmacies including Accredo maintain nationwide networks and can temporarily continue dispensing under the original prescription while the transition PA is processed, but confirm this directly with the pharmacy before assuming coverage continuity [12].

503A Compounding Pharmacies and Alirocumab in Michigan

Some patients ask whether a Michigan 503A compounding pharmacy can prepare alirocumab at lower cost. The answer requires careful interpretation. Alirocumab is a biologics license application (BLA) product, not a small-molecule drug. The FDA's guidance on compounding of biologics states that 503A pharmacies may compound drug products including biologics only under specific conditions and generally may not compound copies of commercially available FDA-approved biologics for the purpose of cost savings [17].

Michigan-licensed 503A pharmacies operate under both state pharmacy board oversight and federal FDCA compounding provisions. Because Praluent is commercially available and not on the FDA drug shortage list, a Michigan 503A pharmacy compounding alirocumab as a substitute for the branded product would likely fall outside lawful compounding boundaries [17]. Patients seeking cost relief should pursue the Sanofi patient assistance program or Michigan Medicaid before considering any compounded alternative.

What Happens If Prior Authorization Is Denied in Michigan

First-pass PA denial rates for PCSK9 inhibitors have historically been high. A 2018 JAMA Cardiology study (N=1,272 PA requests across five health systems) reported a 69% initial denial rate for PCSK9 inhibitors, though 55% of those denials were reversed on appeal when additional clinical documentation was submitted [18].

Michigan payers must provide a written denial notice within the statutory timeframe and must specify the criteria not met. Patients and providers have the right to request:

1. Internal appeal. Submitted within 180 days of denial under Michigan's Insurance Code Section 2213. A physician reviewer not involved in the initial decision must evaluate the appeal.
2. External independent review. If the internal appeal is denied, Michigan law requires access to an independent review organization (IRO) certified by the Michigan Department of Insurance and Financial Services (DIFS) [19].
3. Expedited review. Available when the standard review timeline would seriously jeopardize the patient's health.

The most effective appeal letters cite the ODYSSEY OUTCOMES outcome data directly [2] and quote the 2022 ACC/AHA Class I, Level A recommendation [3] alongside the patient-specific lab values and statin trial history.

Monitoring After Starting Praluent in Michigan

After the first injection, the ACC recommends a repeat fasting lipid panel at four to twelve weeks to confirm LDL-C response [3]. A 50-60% reduction from baseline is expected at the 75 mg dose; if LDL-C remains above goal, the dose can be up-titrated to 150 mg every two weeks [1]. The ODYSSEY OUTCOMES trial showed that alirocumab drove LDL-C to a median of 48 mg/dL at eight months in the treatment arm [2].

Injection site reactions occurred in 7.2% of alirocumab-treated patients vs. 5.1% placebo in pooled phase 3 ODYSSEY trials; most were mild and did not require discontinuation [5]. Neurocognitive adverse events were studied in the EBBINGHAUS trial (N=1,959), which found no significant difference in cognitive function between alirocumab and placebo at 19 months (Cambridge Neuropsychological Test Automated Battery composite score difference: 0.08 to 95% CI -0.17 to 0.34, P=0.53) [20].

Ongoing PA renewals in Michigan typically require a lipid panel result showing treatment response. Keep copies of every lab result obtained after starting alirocumab and request that your provider submit them automatically with each annual PA renewal.